Psychedelic-assisted therapy (PAT) combines preparation, drug administration, and integration, but its methods have remained largely unchanged since the 1950s. Preparation typically lasts two to eight hours over one to three sessions, while drug sessions involve 6-8 hours of monitored introspection with eyeshades and classical music. Integration varies widely, from a single phone call to nine psychotherapy sessions, often using non-directive approaches from psychoanalysis or person-centered therapy. The text argues that these psychosocial components have not been rigorously tested for their relative benefits and recommends updating them with evidence-based treatments like cognitive-behavioral therapy (CBT), which targets shared mechanisms of emotional regulation, cognitive flexibility, and prosocial engagement. Combining psychedelics with structured psychotherapy may produce synergistic, longer-lasting improvements.
A trial is planned to gather initial evidence on whether combining psilocybin with cognitive behavioral therapy is feasible, safe, acceptable, and has psychosocial benefits for people with major depressive disorder. The results will guide larger randomized trials to test this combined treatment's effects and explore how it might work through changes in thinking and emotion. The trial is registered at ClinicalTrials.gov with ID NCT05227612.
Pairing psilocybin with cognitive behavioral therapy (CBT) is acceptable, feasible, and associated with substantial improvements in major depressive disorder. In a small open-label trial, 16 adults with at least moderately severe depression received two psilocybin doses (10 mg and 25 mg) and 12 CBT sessions over four months. All participants completed the 7-month study with no serious adverse events. By treatment end, 13 of 16 showed at least 25% improvement in depressive symptoms, and 9 had fully remitted. Gains in depressive symptoms and psychosocial functioning were sustained three months later, with large effect sizes (Hedges' g = 1.9–2.7). Improvements correlated with better emotion regulation and more positive cognitive schemas.
Two patients in a clinical trial of psilocybin-assisted cognitive behavioral therapy for major depressive disorder had markedly different outcomes. One patient experienced powerful, beneficial effects from psilocybin that led to immediate and sustained antidepressant effects over seven months. The other patient faced significant challenges with psilocybin and reported minimal to no antidepressant effects after the drug sessions. The clinicians' experiences treating both patients are also presented. The authors theorize about future research needed to understand how psilocybin can produce the greatest psychiatric benefit, what patient conditions enable or inhibit benefit, and what psychosocial environment best facilitates psilocybin therapy.